Tesamorelin

Tesamorelin is a synthetic analogue of growth hormone–releasing hormone (GHRH) designed to stimulate endogenous growth hormone (GH) secretion. By acting through the pituitary gland, Tesamorelin increases insulin-like growth factor-1 (IGF-1) while preserving natural hormonal feedback mechanisms. This research paper reviews its mechanism of action, regulatory status, and key clinical findings, with particular emphasis on visceral adipose tissue (VAT) reduction and metabolic outcomes. 

Tesamorelin (TH9507) was approved by the U.S. Food and Drug Administration in 2010 for the reduction of excess visceral fat in adults with HIV-associated lipodystrophy. Unlike exogenous growth hormone administration, Tesamorelin stimulates the body’s natural GH pulsatility. In Australia, Tesamorelin is approved by the Therapeutic Goods Administration. 

Tesamorelin binds to growth hormone–releasing hormone receptors in the anterior pituitary, triggering physiologic GH release. This subsequently elevates IGF-1 levels, promoting lipolysis, protein synthesis, and favourable changes in body composition. The indirect mechanism reduces risks associated with supraphysiologic GH exposure. 

The most consistent and clinically validated outcome of Tesamorelin use is the reduction of visceral adipose tissue. Randomized controlled trials in HIV-associated lipodystrophy populations demonstrate reductions of approximately 15–18% in VAT over 26–52 weeks. Importantly, subcutaneous fat is largely preserved, distinguishing Tesamorelin from generalized weight-loss interventions. 

Beyond VAT reduction, Tesamorelin has demonstrated positive effects on lean body mass, skeletal muscle density, and lipid markers. Studies report reductions in triglycerides, improvements in adiponectin levels, and potential reductions in hepatic steatosis. These findings suggest broader cardiometabolic relevance beyond body composition alone. 

There is increasing interest in Tesamorelin’s potential effects on energy, recovery, sleep quality, and cognitive function. These outcomes are hypothesized to be mediated through IGF-1 signalling, although evidence remains mixed and requires further investigation. 

Tesamorelin is one of the most extensively studied peptides within the GH axis, with strong clinical support for visceral fat reduction and metabolic improvement in specific populations. While off-label and wellness interest continues to grow, current evidence is most robust for VAT-focused and body recomposition outcomes. Ongoing research is required to clarify its broader applications and long-term safety. 

Selected External Research Studies 

1. Falutz J. et al. Effects of Tesamorelin on Visceral Fat in HIV-Infected Patients with Lipodystrophy. New England Journal of Medicine, 2007. 

2. Stanley T.L. et al. Growth Hormone–Releasing Hormone Reduces Visceral Fat and Improves Metabolic Parameters. Journal of Clinical Endocrinology & Metabolism, 2011. 

3. Lo J. et al. Tesamorelin Therapy and Changes in Liver Fat and Metabolic Markers. JAMA, 2014.